Novo Nordisk's GLP-one Pill Approval: A Game Changer

Novo Nordisks new GLP-one pill gains U.S. approval, boosting shares by six percent. The pill, a world first from Wegovys makers, will be available in early January for $149 a month. Novo secures a deal with Trumps direct-to-consumer website, TrumpRx, and gains a competitive edge over Eli Lilly. The approval marks a turnaround for Novo, ending a challenging year and setting the stage for growth in the weight-loss market.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.